First-time CEOs often change their entire strategy after talking to a few investors. This is a red flag signaling a lack of conviction. Investors want to see a CEO who listens and evolves but ultimately sticks to their core, well-researched beliefs, especially when faced with disarming questions.
Aim to make decisions when you have between 40% and 70% of the necessary information. Striving for more than 70% leads to slow, inefficient decision-making, allowing competitors to get ahead. The key is making timely, good-enough decisions, not perfect ones.
A leader's ability to make fast, informed decisions depends on their network. The ultimate test of that network's effectiveness is whether you are just one text message away from getting the crucial inputs or expert opinions needed to fill an information gap quickly.
A CEO is always selling their company's story—to investors, hires, and customers. An investor's first filter is whether the CEO can get them interested and excited in the first 30 seconds. If it takes a 35-slide deck to explain the vision, the opportunity is likely already lost.
Leaders, especially those from highly individualistic fields like surgery, must evolve from a top-down, self-reliant style to one that orchestrates diverse opinions. This approach fosters better problem-solving by surrounding oneself with people who have different, often stronger, skills.
In Biotech, risk is removed pre-FDA approval via clinical trials, making a Chief Development Officer (clinical, regulatory, manufacturing) the most critical hire. In many MedTech sectors, risk is removed post-FDA approval via market adoption, making a Chief Commercial Officer paramount.